An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this screening portion of this clinical research study is to learn if you are
eligible to take part in a clinical research study using Tarceva (erlotinib hydrochloride)
and either Erbitux (cetuximab), Velcade (bortezomib), or Sprycel (dasatinib).
If the results of the screening portion of this clinical research study show that you are
eligible to take part in one of the studies described above, the study drug that you will be
assigned to take will depend on the results of biomarker analysis performed as a part of the
screening tests described below. Biomarkers are chemical "markers" in the blood/tissue that
may be related to how your body might react to the study drug.